To achieve durable responses, combination therapies simultaneously targeting multiple, independent pathways (i.e. MAPK and PI3K and/or immune-response) should be explored in the setting of treatment naïve c-Kit mutant melanoma patients and patients with acquired resistance to c-Kit inhibitors. Here, KIT is linked to melanoma.